胰岛素抵抗替代品在胆结石疾病中的预测作用
Jia Liu1, Zixuan Hu2, Dele Bo1
1Physical Examination Center, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Medicine
|April 7, 2025
概括
胰岛素耐药替代品,包括腰围三甘油糖指数 (TyG-WC) 和体重指数 (TyG-BMI),与胆结石疾病风险有关. TyG-WC和TyG-BMI显示出显著的预测价值,特别是在女性中与年龄相结合时.
科学领域:
- 代谢综合征和心血管健康
- 胃肠病学和肝病学
背景情况:
- 胰岛素抵抗 (IR) 与心血管疾病有关.
- 对于胆结石病 (GSD) 的IR替代品的预测作用需要进一步研究.
研究的目的:
- 评估四种IR替代体与GSD风险之间的关联.
- 评估这些替代品对GSD的预测能力.
主要方法:
- 对19696名参与者的回顾性横截面研究.
- 分析了甘油三指数 (TyG),甘油三指数 (TyG-WC),甘油三指数 (TyG-BMI) 和甘油三/高血糖水平 (HDL-C) 的比率.
- 后勤回归和ROC曲线分析以确定预测值.
主要成果:
- 在胆结石疾病组中,所有四种IR替代物均显著高于胆结石疾病组.
- 经过调整后,TyG-WC和TyG-BMI是两种性别GSD的独立预测因素.
- 预测能力在女性中更强,并且与年龄相结合时进一步改善.
结论:
- TyG-WC和TyG-BMI是胆结石疾病患病率的重要风险因素.
- 这些指数,特别是与年龄相结合时,显示出GSD的良好预测价值,特别是在女性中.
相关概念视频
Acute Pancreatitis II: Clinical Manifestations and Management
75
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
75
Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
Glucagon-like Receptor Agonists
276
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
276
Ultrasound II: Endoscopic Ultrasound and FibroScan
60
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
60
Chronic Pancreatitis I: Introduction
56
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
56
Dipeptidyl Peptidase 4 Inhibitors
142
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
142


